OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« Federal Circuit Affirms Denial of Somerset Pharma's Interim Patent Term Extension on Depression Patch | Main | Hatch-Waxman Tracker Update »

August 03, 2007

Pharma News Briefs

  • FDA Law Blog had a post Thursday about "The Dog Ate My Homework Act," which would give a reprieve to companies that miss the deadline for filing a patent term extension request.
  • Pharmalot had this post Wednesday, reporting that Congress has delayed the FDA bill until September.
  • Patently-O reported Wednesday on the Federal Circuit's decision on Washington, D.C.'s drug price law.  PhRMA made a press release on the decision.  The Washington Post published this article on the case.
  • Tuesday, Wyeth announced a deal with Teva and Sun concerning generic Protonix.  Today, Teva announced that FDA approved its ANDA for Protonix.
  • Investor's Business Daily had an interesting article last week, "RNAi Stirs Excitement in Big Pharma."
  • The Patent Prospector had a neat post last week, "Dealing with KSR."

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.